Tecnovigilancia and Market Surveillance in Nicaragua

1. Key takeaways

Nicaragua moves part of the vigilance obligation forward into the registration stage. Item 12 j of Chapter 6 requires a detailed technovigilance plan covering complaints, sanitary alerts, adverse reactions, events or adverse incidents whether mild or serious, and arrangements for tracking products withdrawn because of quality defects or because of those events, and it requires the plan to name the person responsible for executing it within the country. After placing on the market, market surveillance sampling is carried out by the health vigilance department and the quality control laboratory directorate of DDM, which attend the business premises to take samples within a maximum of sixty working days after the renewal certificate is issued.

• The technovigilance plan is a registration document, not a post-market afterthought.
• Five subject areas must be addressed, and a named in-country responsible person is mandatory.
• Two sampling triggers exist with different starting points and different release documents.
• Sampling after renewal occurs within sixty working days of the renewal certificate.
• A failed batch follows a ninety-day replacement and a twenty-working-day destruction rule.
• The scope of products subject to testing is defined by an external guide whose content is not reproduced here.

2. Legal basis

The provisions combine the registration-stage requirement in Chapter 6 with the consequences in Chapter 10 and the sampling mechanics in Annex I of RA 0007/2025.

3. Expert insights

The first point is timing. Chapter 6, item 12 j requires the technovigilance plan at the registration stage and requires it to name the in-country responsible person. Post-market obligations are therefore pulled forward into market access: without the plan the registration dossier is incomplete. This differs from the more common approach of building a vigilance system after the product has been approved.

The second point is the content list, which is a list of five parallel subjects rather than a general statement: complaints (reclamos), sanitary alerts (alertas sanitarias), adverse reactions (reacciones adversas), events or adverse incidents (eventos o incidentes adversos, expressly including mild and serious cases), and withdrawal from the market (retiro del mercado). A single sentence stating that a vigilance system exists does not satisfy the requirement.

The third point is that post-market sampling has two triggers with different rules. The first-import inspection for a new registration sits in article 14 of Annex I, starts from customs clearance and produces the “Autorización de Primera Importación”. The market surveillance sampling after renewal sits in article 15 of Annex I, starts from issuance of the renewal certificate and produces the “Autorización de Comercialización”. The two procedures cannot be substituted for one another.

The fourth point is the sampling deadline. For post-renewal sampling it is sixty working days from the date the renewal certificate is issued, under article 15, paragraph 3 of Annex I. The applicant has to request the inspection before that point: within fifteen working days of the renewal certificate, or, where there is no stock on the market at renewal, within fifteen working days from customs clearance of the import made after renewal, as provided in note 2.

The fifth point is the consequence chain for a failed result, which matches the first-import regime: a ninety-day batch replacement, destruction within twenty working days under ANRS supervision with the importer bearing the cost, and cancellation of the registration if the replacement also fails, under article 15, paragraphs 5 and 6 and notes 2 and 3. Renewal is not an automatic continuation of the right to sell.

The sixth point is scope. The products subject to testing are defined by an external document, RA 0029/2024, “Guía del programa de vigilancia de mercado para el seguimiento de la calidad de productos médicos”. The full text of that guide was not available for this guide, so no view is offered on which products must be submitted for testing. That gap is deliberate and should be closed by confirming the current DDM position.

4. Practical recommendations

• Complete the technovigilance plan at the dossier stage, addressing each of the five subjects and naming the in-country responsible person, as required by Chapter 6, item 12 j.
• Link the operation of the plan to Chapter 10, items 6, 8 and 9, and assess whether an international alert is serious or of high impact as soon as it appears.
• Keep a register with both sampling triggers: first import, at fifteen working days from customs clearance, and post-renewal, at fifteen working days from issuance with sampling within sixty working days.
• Where there is no stock at renewal, defer the inspection request under note 2 to fifteen working days from customs clearance and retain evidence that no stock was held.
• Arrange destruction of a failed batch within twenty working days under ANRS supervision at the importer’s cost, and keep the records.
• Confirm in writing with DDM whether the product falls within the testing scope of RA 0029/2024 rather than assuming an exemption.

5. Verification checklist

• □ The technovigilance plan addresses all five subjects and names the in-country responsible person.
• □ Operation of the plan is linked to the triggers in Chapter 10, items 6, 8 and 9.
• □ A register covers both sampling triggers, first import and post-renewal.
• □ Where no stock was held at renewal, the inspection request was deferred under note 2 and the evidence retained.
• □ Destruction of a failed batch is arranged against the three requirements and documented.
• □ Written confirmation has been obtained from DDM on whether the product falls within the scope of RA 0029/2024.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com